|Articles|June 6, 2013
From ASCO: Updates in HER2-positive breast cancers
Author(s)Debu Tripathy
Advertisement
Debu Tripathy, MD, editor-in-chief of CURE, discusses preliminary studies on combining Herceptin (trastuzumab) with existing drugs to treat HER2-positive breast cancer. These highlighted studies were presented at the 2013 American Society of Clinical Oncology's annual meeting in Chicago.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on CURE
1
A New Option Without Traditional Chemotherapy for Ph+ ALL
2
Azacitidine Plus Venclexta Superior to Chemo in Acute AML
3
Jaypirca Matches Imbruvica's Effectiveness for CLL, With Hints of Long-Term Benefit
4
Elrexfio Maintains Responses in Elderly, Frail Patients With Multiple Myeloma
5
